Smoking Rates Hit Historic Low in US amid Pandemic

Mar.23.2022
Smoking Rates Hit Historic Low in US amid Pandemic
Smoking rates hit an all-time low in the US during the first year of the pandemic, attributed to public health campaigns and lifestyle changes.

According to foreign media reports on March 17, 2022, New York - in the first year of the COVID-19 pandemic, an increasing number of Americans have been abusing alcohol or using illegal drugs, but apparently not smoking.

 

According to survey data released on Thursday by the U.S. Centers for Disease Control and Prevention, smoking rates in the United States have reached a historic low in 2020, with only 1 in 8 adults reporting current use. The CDC also reported a decrease in adult e-cigarette usage.

 

Officials from the Disease Prevention and Control Center attributed this decline to public health campaigns and policies. However, outside experts suggest that increased prices for tobacco products and changes in lifestyle due to epidemics may have also played a role.

 

People who are mainly social smokers no longer have this situation," said Megan Roberts, a researcher at Ohio State University who focuses on tobacco product use among young people and adolescents.

 

More importantly, parents who suddenly had to stay home full-time with their children may have already cut back on expenses. Roberts also added that some individuals may have quit smoking after reports came out suggesting that smokers are more likely to develop severe illnesses if infected with COVID-19.

 

According to a report from the Centers for Disease Control and Prevention, based on a survey of over 31,000 American adults, 19% of Americans used at least one tobacco product in 2020, which is lower than the approximately 21% reported in 2019.

 

The use of cigars, smokeless tobacco, and pipes remain unchanged. Currently, the usage rate of electronic cigarettes has decreased from 4.5% in the previous year to 3.7%.

 

Cigarettes are the most commonly used tobacco product, with 12.5% of adults using them, which is lower than the 14% average.

 

For a long time, public health officials have believed that smoking - a risk factor for lung cancer, heart disease and stroke - is the leading cause of preventable deaths in the United States.

 

In 1965, 42% of American adults were smokers.

 

For several decades, this ratio has been gradually declining for various reasons, including taxes and smoking bans in workplaces and restaurants. However, some experts argue that a significant portion of the recent decline is due to the recent increase in prices.

 

For example, British American Tobacco - a company that produces brands such as Camel, Lucky Strike, and Newport - increased their prices fourfold in 2020, resulting in a total increase of around 50 cents per pack.

 

Interestingly, the amount of cigarettes sold in the United States actually increased in 2020, according to a report from the Federal Trade Commission. This is the first such growth in twenty years.

 

While there may be fewer smokers, those who do smoke tend to smoke more heavily.

 

This is a viable hypothesis - that people have more opportunities to smoke because they are not working," said David Sweanor, the global tobacco policy expert at the University of Ottawa.

 

He said that the investigation by the Disease Prevention and Control Center may also underestimate the number of smokers, either because some interviewees are dishonest or because the investigation missed too many smokers.

 

Other surveys have indicated that alcohol and illegal drug use have increased for many people during the first year of the pandemic.

 

(Source: Associated Press)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08